EDITORS' DESK

  • A Glimpse Into Thailand’s Ongoing Life Sciences Transformation
    A Glimpse Into Thailand’s Ongoing Life Sciences Transformation

    During my visit to Thailand, I was privy, not only to the particularly innovative research goals being pursued, but also to a number of challenges the country has recognized and hopes to address within the next few years to encourage a stronger, more diverse industry.

What Thailand Revealed About U.S. Pharma R&D

A few weeks ago, I was invited by the Thailand Board of Investment to attend a media trip to learn about the country’s budding life sciences industry. Entering Thailand, a country in which the government is pushing more investment and education in the sciences, was even more striking and meaningful to me given the current scientific climate in the U.S.

Top 5 Biosimilar Developments Of 2016

In the spirit of this list-making season, I compiled what I thought were the five most important biosimilar-related triumphs in the past year. Many of these events were widely covered by the media and will play an influential role in how the biosimilar industry unfolds through 2017 and beyond.

Are You The Future of Pharmaceutical Development?

Pfizer's Bernie Huyghe and ADC Therapeutics' Michael Mulkerrin get bushwhacked with this question in a public forum. Their open replies will help each one of you to your own personal assessment. Be prepared for some soul searching.

The Case For Moving The EMA To Ireland

Relocating an organization as large as the EMA, which employs upwards of 1,000 people in London, will be no easy feat. As such, IDA Ireland, an agency that supports companies in Ireland and promotes foreign direct investments in the country, is working to compile information on why Ireland would be a good location for the EMA.

More From Our Editors

GUEST CONTRIBUTORS

  • Rapid Growth In Life Science Sector Constrains Capital Projects Supply Chain

    According to the latest PharmSource Trend Report, "Bio/Pharma CapEx Trends 2016", biopharma companies have invested over $150 billion in new plants and equipment in the past five years. As this sector continues on an upward trend, it is placing significant pressure on the supply chain.

  • How To Build A Value-Added GMP Supplier Management Program

    Typically, supplier management programs use a supplier survey or an on-site audit to verify if a supplier is compliant with the requirements of a standard or regulation. However, for a supplier management program to provide added value to an organization, the supplier evaluation should look beyond the requirements of a standard or regulation.

More From Guest Contributors

PHARMA ONLINE WHITE PAPERS

More Pharma Onine White Papers

INDUSTRY INSIGHTS

More Industry Insights

PHARMA INDUSTRY EVENTS

12th Clinical Trial Billing and Research Compliance Conference February 25 - 28, 2018
Lake Buena Vista, FL
AI-PI Drug Discovery Summit 2018 February 26 - 28, 2018
San Francisco, CA
DUPHAT 2018 February 27, 2018 - March 1, 2018
Dubai
Cell Therapy: Process Design Considerations To Support Commercialization February 27, 2018
1pm-2:30pm EST, Online Training
More Industry Events